Loading clinical trials...
Loading clinical trials...
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Belimumab (Benlysta ®) is a human immunoglobulin...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Tianjin Medical University General Hospital
Collaborators
NCT05145361 · NMO Spectrum Disorder
NCT05004493 · Antibody-mediated Rejection, NMO Spectrum Disorder, and more
NCT05154370 · Multiple Sclerosis, NMO Spectrum Disorder, and more
NCT05403138 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, and more
NCT02028884 · Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions